Fairvalue-Calculator Fairvalue-Calculator
EN DE

Daxor Corporation (DXR) Fair Value & Analysis

Healthcare · US · Market cap $56.9M

Price$10.50
Fair Value$26.70
Upside+154.3%
Quality95/100
Evidence: Medium Range $20.03 – $33.38

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Daxor Corporation (DXR) currently trades at $10.50, while our model-based Fair Value estimate is $26.70 — implying the stock looks roughly 154.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -55% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -42% Medline Inc (MDLN) -13% Becton, Dickinson and Company (BDX) -28% Alcon Inc (ALC) -33%

Frequently asked questions

Is Daxor Corporation (DXR) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $26.70 versus a price of $10.50 — about +154% (undervalued). Model-based estimate, not financial advice.
What is the fair value of DXR?
Our 21-model fair value for Daxor Corporation is $26.70 (as of Jun 25, 2026), built from audited fundamentals. The current price is $10.50.
What is the quality score of DXR?
Daxor Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.